X

Drug Profile

Pioglitazone - Boryung Pharmaceutical

Latest Information Update: 24 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boryung Pharmaceutical
Class Antihyperglycaemics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Type 2 diabetes mellitus

Most Recent Events

09 Sep 2024 Efficacy and adverse event data from a phase III trial in Type 2 diabetes mellitus presented at the 60^th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
10 Mar 2023 Boryung Pharmaceutical completes a phase III trial in Type2 Diabetes in South Korea (Unspecified) (NCT04885712)
28 May 2021 Phase-III clinical trials in Type 2 diabetes mellitus in South Korea (unspecified route) (NCT04885712)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com